Zymeworks (ZYME) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Zymeworks Inc., a clinical-stage biotech firm, has announced their participation in the Bank of America Securities Health Care Conference and J.P. Morgan Biotech Virtual Call Series on May 15th, emphasizing their commitment to developing biotherapeutics for challenging diseases. They are advancing a diverse pipeline, including zanidatamab, a HER2-targeted bispecific antibody, which is under evaluation in global clinical trials and pending accelerated approval by the FDA for HER2-positive biliary tract cancer.
For further insights into ZYME stock, check out TipRanks’ Stock Analysis page.
